5 completed, 2 unknown, 1 recruiting. 8 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Completed 5, Unknown 2, Recruiting 1 |
Follow SK Bioscience Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years NBP608 (Mid Potency), NBP608 (Low Potency), Varivax® - Varicella (Chickenpox) | Phase 3 | Recruiting | SK Bioscience Co., Ltd. | 780 | 2026-07-04 | 2026-09-15 |
| Immunogenicity and Safety Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine(GBP510) Adjuvanted with AS03 in Adults Aged 18 Years and Older GBP510 adjuvanted with AS03, Placebo (Normal Saline) - COVID-19 | Phase 3 | Completed | SK Bioscience Co., Ltd. | 840 | 2022-12-09 | 2024-10-16 |
| Immunogenicity and Safety Study of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine (GBP510) Adjuvanted With AS03 (COVID-19) GBP510 adjuvanted with AS03 (Receptor-Binding Domain(RBD) 25ug/dose), ChAdOx1-S not less than 2.5 × 10^8 infectious units - Covid19 | Phase 3 | Completed | SK Bioscience Co., Ltd. | 4036 | 2021-08-30 | 2024-04-08 |
| Immune Equivalence Between Multi-dose and Single Dose Formulation of Vi-DT and Their Overall Safety (Phase III) Vi-DT (Multi-dose formulation), Vi-DT (Single dose formulation), Control Vaccine - Typhoid | Phase 3 | Completed | International Vaccine Institute | 1800 | 2020-02-04 | 2021-08-27 |
| Immune Non-inferiority and Safety of a Vi-DT Typhoid Conjugate Vaccine Test Vaccine Vi-DT Typhoid conjugate, Control Vaccine Typbar TCV® - Typhoid | Phase 3 | Unknown | International Vaccine Institute | 1800 | 2019-11-15 | 2020-04-22 |
| A Trial to Assess the Safety, Immunogenicity and Efficacy of a Trivalent Rotavirus P2-VP8 Subunit Vaccine in Prevention of Severe Rotavirus Gastroenteritis in Healthy Infants in Africa and India TV P2-VP8, Rotarix - Rotavirus Infection of Children | Phase 3 | Unknown | PATH | 8200 | 2019-10-10 | 2021-04-09 |
| Immunogenicity and Safety of NBP607-QIV Compared to Agrippal in Children Aged 6 to 35 Months NBP607-QIV, Agrippal - Influenza | Phase 3 | Completed | SK Bioscience Co., Ltd. | 676 | 2018-10-25 | 2022-05-11 |
| Immunogenicity and Safety of NBP608 Compared to Varivax in Healthy Children 12 Months to 12 Years of Age NBP608, Varivax - Varicella | Phase 3 | Completed | SK Bioscience Co., Ltd. | 516 | 2016-07-14 | 2019-05-08 |
COVID-19 (2) · Chickenpox (2) · Typhoid Fever (2) · Influenza, Human (1)
Chickenpox Vaccine (2) · Saline Solution (2) · Diphtheria Toxoid (1) · Dosage Forms (1) · GBP510 vaccine (1) · RIX4414 vaccine (1)
Philippines (4) · South Korea (3) · Nepal (2) · Thailand (2) · Colombia (1) · Honduras (1) · New Zealand (1) · Ukraine (1) · Vietnam (1) · Zambia (1)
Desiree Witte, MD (1) · Ganesh Kumar Rai, MD (1) · George Armah, PhD (1) · Hee Jin Cheong (1) · Josefina C Carlos, MD (1) · Roma Chilengi, MD (1) · Santa K Das, MD (1) · Yun Kyung Kim, MD (1)
PMID 34942090, PMID 35664443, PMID 35988541, PMID 37711219, PMID 41319434